-
[About us] Journal 'Cytokines & Inflammation'

197376, -, . . , . 12,

.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
: (812) 543 52 14
E-mail:
Web: www.cytokines.ru


  


Year 2018
1-4 issues

About journal

Current year
Archive

Columns
Subscription

Rules for authors

Contact us

Search

Site map

Our partners:
 English language
Site map Contact us

Contents | Next article

Journal 'Cytokines & inflammation', 2016, No. 3

Subscribe for 2019 year

Order this issue

Order PDF of this article

Reviews

Number 3'2016

The experience of biosimilar monoclonal antibody drug registration. Communication 2. Preclinical study

Zh.I. Avdeeva, A.A. Soldatov, N.A. Alpatova, Yu.V. Olefir, V.A. Merkulov, V.P. Bondarev, V.D. Mosyagin

The review provides information on the experience of the first biosimilar drugs ("biosimilars") based on monoclonal antibodies registration. In June 2013, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Medicines (EMA) recommended licensing Remsima and Inflectra as biosimilars containing infliximab. Infliximab is a chimeric monoclonal antibody that is capable of binding the soluble and transmembrane forms of tumor necrosis factor alpha with a high degree of affinity. The drug based on such antibodies was first licensed in the EU in August 1999 under the name Remicade. These preparations are similar to the original Remicade preparation. Information on the results obtained during comparative studies of pharmacological properties, pharmacokinetic parameters, as well as the results of toxicological studies are presented. The analysis of data on the evaluation of physico-chemical characteristics, biological activity and preclinical studies of drugs, suggesting a high degree of similarity between the developed and original (referent) preparations are presented. The stage of preclinical comparative research precedes the subsequent comparative clinical studies. (Cytokines and Inflammation. 2016. Vol. 15. 34. P. 221229.).

Keywords: monoclonal antibodies, biosimilars, biosimilar biopreparations, preclinical researches, pharmacological properties, pharmacokinetic studies, toxicological studies.

Contents | Next article


© 2007-2019 Cytokines and inflammation